How will the PROSPECT trial presented at ASCO 2023 change your current management of early rectal cancer?  

I can’t overstate how much credit the Principal Investigator, Dr. @Deb Schrag, deserves for successfully completing the PROSPECT trial. The oncology community, particularly the radiation oncology community, was concerned that omitting radiation would put patients at risk. It was difficult and ...

PROSPECT is an important study with some equally important caveats. There are some patients for whom radiation can be omitted in the treatment of rectal cancer. However, for lower rectal cancers that need an APR, or T4 or N2 tumors, or those that don’t achieve at least 20% shrinkage with FOLFO...

Total Neoadjuvant Treatment (TNT) is the preferred approach for locally advanced rectal cancer based on the benefits including early prevention or eradication of micrometastases, higher rates of pathologic complete response, longer progression free survival, decreased length of time for ileostomy, i...